Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical
activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced
solid tumors that have a KRAS G12C mutation.